Edition:
India

Novus Therapeutics Inc (NVUS.OQ)

NVUS.OQ on NASDAQ Stock Exchange Capital Market

4.28USD
9:11pm IST
Change (% chg)

$0.07 (+1.66%)
Prev Close
$4.21
Open
$4.34
Day's High
$4.34
Day's Low
$4.28
Volume
182
Avg. Vol
3,378
52-wk High
$15.12
52-wk Low
$3.42

Latest Key Developments (Source: Significant Developments)

Novus Therapeutics Inc reported Q3 $0.43 loss per share​
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​.  Full Article

Novus Therapeutics reports third quarter 2017 results
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics reports third quarter 2017 results.Q3 loss per share $0.43.  Full Article

Tokai Pharmaceuticals appoints John S. Mcbride CFO
Wednesday, 3 Aug 2016 

Tokai Pharmaceuticals Inc : Lee H. Kalowski, chief financial officer will cease employment effective august 31, 2016 - SEC filing . CFO, EVP, business operations and general counsel, will cease employment in relation to previously announced workforce reduction . Previously announced retirement of Karen J. Ferrante, chief medical officer, will become effective on august 31, 2016 .Appointed John S. Mcbride chief financial officer effective September 1, 2016.  Full Article

Tokai Pharmaceuticals says reducing workforce by about 60 pct
Saturday, 30 Jul 2016 

Tokai Pharmaceuticals Inc : Tokai pharmaceuticals announces reduction in force . Workforce reduction plan expected to be largely completed by end of q3 of 2016. . Says expects reduction in force to result in approximately $4.2 million in reduced annualized operating expenses . Also expects to incur a charge in q3 of 2016 of approximately $1.3 million related to reduction . Reducing its workforce by approximately 60 percent, to a total of 10 full-time equivalent employees . Says reducing its workforce by approximately 60 percent, to a total of 10 full-time equivalent employees . Says reduction plan expected to be largely completed by end of q3 of 2016 .Says also expects to incur a charge in q3 of 2016 of approximately $1.3 million related to reduction, including severance.  Full Article

Tokai Pharmaceuticals posts Q1 loss per share $0.51
Tuesday, 10 May 2016 

Tokai Pharmaceuticals Inc : Tokai Pharmaceuticals reports first quarter 2016 financial results . Q1 loss per share $0.51 .Q1 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Novus Therapeutics Inc reported Q3 $0.43 loss per share​

* Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​ Source text: (http://bit.ly/2hldAkp) Further company coverage: